德琪醫藥-B(06996)：國家藥監局批准 ELTANEXOR 用於治療晚期實體瘤 IB/II 期臨牀試驗的 IND 申請

智通財經
2021.05.14 00:08
智通財經 APP 訊，德琪醫藥-B(06996) 發佈公告，本公司已獲國家藥品監督管理局批准 Eltanexor 在中國用於治療晚期實體瘤 IB/II 期臨牀試驗的臨牀試驗 (IND) 申請。
Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.